Pfizer registers Phase 3 trials in alopecia areata and chronic migraine; two Phase 1 studies open

This week's registry updates cover two new Phase 3 programs and several early-phase studies.

• Pfizer is recruiting for a Phase 3 trial of ritlecitinib in moderate alopecia areata for people 12 and older with patchy hair loss. The study's primary purpose is treatment, with quadruple masking and an estimated enrollment of 336 participants.¹ The main goal is to compare the difference in the proportion of participants achieving a Severity of Alopecia Tool (SALT) score of 0 at Week 24 between ritlecitinib 50 mg once daily and placebo.¹
• Pfizer is recruiting for a Phase 3 trial testing once-daily rimegepant for prevention of chronic migraine, comparing it against placebo. The study aims to find out whether once-daily rimegepant works better than placebo at cutting the number of monthly migraine days compared to the earlier observation period.² Enrollment is estimated at 400 participants.²
• Pfizer's Phase 1 study of PF-08642534 in adults with obesity is recruiting to evaluate whether different doses can be taken safely and how they are tolerated, and how the body absorbs and removes the drug.³ Enrollment is estimated at 120 participants.³
• Pfizer's Phase 1 crossover study of prifetrastat is not yet recruiting and will look at how a high-fat, high-calorie meal affects drug absorption in healthy adults, titled "A Study to Learn About How Food Affects the Uptake of Study Medicine Prifetrastat Into the Blood in Healthy Adults." Results are meant to guide food-intake instructions for people in future prifetrastat studies and for patients after marketing.⁴ Enrollment is estimated at 12 participants.⁴
• BioNTech is sponsoring a Phase 4 trial of an updated BNT162b2 COVID-19 vaccine in adults 18 to 64, with Pfizer as collaborator. The study is recruiting 200 estimated participants⁵ to compare BNT162b2 against a Tdap vaccine for safety and spike protein levels.